Compare Deutsche Bank AG (DB) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Sana Biotechnology Inc — how do they compare? Deutsche Bank AG trades at $33.5 (market cap $62.42B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Deutsche Bank AG is far larger — about 74.6× Sana Biotechnology Inc's market cap, and Deutsche Bank AG pays a 3.46% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Sana Biotechnology Inc for 23 Days on average.
| DB | SANA | |
|---|---|---|
Market Cap | $62.42B | $836.71M |
Volume | 2,918,760 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $41.56 | $5.92 |
52-Week Low | $28.37 | $2.68 |
Typical Hold Time | 80 Days | 23 Days |
Enterprise Value | $77.06B | $749.96M |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.55, down 4.5% on concerns about Q3 investment banking revenue. The stock shows attractive valuation metrics with P/E of 9.09 and P/B of 0.71, while fundamentals improved with 2025 net income reaching $6.93B and profit margin expanding to 21.59%. Technical indicators signal bearish momentum with the price near key support at $33. Recent news highlights the bank's strategic focus on wealth management growth and 2028 return targets.
The outlook remains balanced - strong fundamentals and undervaluation provide upside potential, but near-term headwinds in investment banking and technical weakness suggest cautious optimism. Key risks include execution on strategic targets and market-sensitive revenue streams, while analyst consensus leans neutral with 58% hold ratings.
SANA Biotechnology trades at $2.72, down 1.09% with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with negative revenue, a net loss of $244.17 million in 2025, and negative cash flow. However, analyst sentiment remains positive with 82% buy ratings and recent conference presentations highlighting ongoing research in engineered cell therapies.
The outlook is highly speculative given the pre-revenue stage and substantial losses. Investment opportunity lies in the potential of SANA's biotechnology platform, but risks include cash burn, clinical trial outcomes, and competitive pressures. Wall Street maintains cautious optimism despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
